Loading...

TERN TERNS PHARMACEUTICALS INC Expansion Plans 8-K Filing

TRNS

TRN

TERNS PHARMACEUTICALS INC

(TERN)

2025 8-K

Merger Completed

FDA Approval News

Merger Announcement

License Agreement Update

Company Priorities Update

Public Offering Announcement

Clinical Trial Update

Financial Results Report

Clinical Trial Results

Financial Statements

Financial Statements

Financial Results

Management Change

Management Changes

Financial Update

Financial Results

Public Offering

Positive Trial Results

Earnings Reports

Executive Leadership Transi...

Lease Extension

Earnings Reports

Financial Results Announcement

Appointment of CEO and Dire...

Earnings Reports

Bylaws Amendment

Earnings Reports

Leadership Transition

Sales Agreement

Earnings Reports

Financial Results Announcement

Assurance of Operations and...

External Links:

On December 8, 2025, Terns Pharmaceuticals announced expanded data from the Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia, showing a 74% major molecular response (MMR) rate among patients after 24 weeks, with promising safety data and no dose limiting toxicities observed.

AI Assistant

TERNS PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.